静脉血栓栓塞症的急性期治疗
所有无绝对禁忌证的静脉血栓栓塞症(VTE)患者均应接受抗凝治疗,初始抗凝对降低死亡率、预防早期复发和改善长期结局至关重要。直接口服抗凝药(DOAC)因固定剂量、无需监测且与大出血风险降低相关(RR 0.61;95%CI 0.45-0.83),是多数急性VTE患者的首选。仅不足10%的患者需溶栓或介入再灌注,多数急性DVT及部分血流动力学稳定的PE患者可安全门诊管理。
要点
- 无绝对禁忌证的VTE患者均应抗凝,初始治疗影响死亡与复发。
- 多数急性VTE首选DOAC,大出血风险低于传统抗凝(RR 0.61)。
- 仅不足10%患者需溶栓或介入,多为血流动力学不稳定的PE。
核心结论
- 多数急性VTE患者首选固定剂量DOAC抗凝,其大出血风险低于传统抗凝且复发风险相似。
研究设计与样本
- 本文为综述,总结急性VTE抗凝治疗及再灌注治疗的证据与患者管理策略。
主要发现
- DOAC与传统抗凝相比,大出血相对风险为0.61(95%CI 0.45-0.83),复发相对风险为0.90(95%CI 0.77-1.06)。
- 严重肾功能衰竭、抗磷脂综合征或癌症患者仍可分别选用维生素K拮抗剂或低分子肝素作为DOAC的替代。
- 需溶栓或介入再灌注的患者可能不足10%,主要为血流动力学不稳定的急性肺栓塞,少数为威胁肢体的近端DVT。
关键数值与推荐
- DOAC用于多数急性VTE患者,固定剂量且无需实验室监测。
- 大出血RR 0.61(95%CI 0.45-0.83),复发RR 0.90(95%CI 0.77-1.06),均为DOAC对比传统抗凝。
- 严重肾功能衰竭或抗磷脂综合征可选维生素K拮抗剂,癌症患者可选低分子肝素。
- 可能不足10%的患者需要溶栓或介入再灌注治疗。
临床怎么用
- 根据临床表现严重程度、合并症及门诊治疗可行性制定个体化抗凝与处置方案。
- 多数急性DVT及部分血流动力学稳定的急性PE患者可安全门诊管理。
- 治疗选择应结合临床试验证据与本地经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
All patients with venous thromboembolism (VTE) should receive anticoagulant treatment in the absence of absolute contraindications. Initial anticoagulant treatment is crucial for reducing mortality, preventing early recurrences, and improving long-term outcome. Treatment and patient disposition should be tailored to the severity of clinical presentation, to comorbidities, and to the potential to receive appropriate care in the outpatient setting. Direct oral anticoagulants (DOACs) used in fixed doses without laboratory monitoring are the agents of choice for the treatment of acute VTE in the majority of patients. In comparison with conventional anticoagulation (parenteral anticoagulants followed by vitamin K antagonists), these agents showed improved safety (relative risk [RR] of major bleeding, 0.61; 95% confidence interval [CI], 0.45-0.83) with a similar risk of recurrence (RR, 0.90; 95% CI, 0.77-1.06). Vitamin K antagonists or low molecular weight heparins are still alternatives to DOACs for the treatment of VTE in specific patient categories such as those with severe renal failure or antiphospholipid syndrome, or cancer, respectively. In addition to therapeutic anticoagulation, probably less than 10% of patients require reperfusion by thrombolysis or interventional treatments; those patients are hemodynamically unstable with acute pulmonary embolism, and a minority of them have proximal limb-threatening deep vein thrombosis (DVT). The choice of treatment should be driven by the combination of evidence from clinical trials and by local expertise. The majority of patients with acute DVT and a proportion of selected hemodynamically stable patients with acute pulmonary embolism can be safely managed as outpatients.
引用
- Becattini C, Agnelli G. Acute treatment of venous thromboembolism. Blood. 2020. PMID: 31917399. doi:10.1182/blood.2019001881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。